Nephrocare Health IPO: Everything You Need to Know

Written by Jainam Resources

Last Updated on: January 8, 2026

The dialysis care segment in India has been expanding steadily, and Nephrocare Health Services Ltd. is among the recognised providers operating in this space. The company is launching its Initial Public Offering (IPO) to raise capital for growth and to facilitate partial exits for existing shareholders. This development was reported publicly through market filings and financial news platforms. 

In this blog, we break down the Nephrocare Health IPO details, including issue size, price band, lot size, use of proceeds, financials, strengths, risks, allotment & listing dates, so investors can evaluate the offering with clarity.

Nephrocare Health Services Ltd IPO Overview

Nephrocare Health Services Ltd. is one of the biggest dialysis networks in India. It provides dialysis care through a network of clinics throughout India and around the world. The company is now looking for money through its Nephrocare Health IPO to speed up its growth and pay off its debts.

Key IPO Details

• Issue Size: ₹871.05 Crore (Fresh Issue: ₹353.4 Cr + Offer for Sale: ₹517.65 Cr)
  
• Price Range: ₹438 – ₹460 per share
  
• Face Value: ₹2 per share
  
• Lot Size: 32 shares
  
• IPO Date: Opens on 10th December 2025 and closes on 12th December 2025
  
• Tentative Allotment Date: 15th December 2025
  
• Tentative Listing Date: 17th December 2025
  
• Minimum Investment: ₹14,016 (for the upper band of the price)

Nephrocare Health Services: A Business Overview

Nephrocare Health Services Ltd. is a top company in the dialysis care field. It has 519 clinics around the world, 468 of which are in India and the rest are in places like the Philippines, Nepal, and Uzbekistan. The organisation offers a lot of different types of dialysis services, such as in-clinic dialysis, home dialysis, mobile dialysis on wheels, holiday dialysis, and more.

Nephrocare is ready to fulfil the expanding need for dialysis in both urban and underserved tier II and tier III areas, with a focus on patients with chronic kidney disease (CKD). The organisation has made a lot of progress in offering therapy through protocol-led methods and new technologies like Renova, a cloud-based dialyser reprocessing system.

Objectives of the Nephrocare IPO

The proceeds from the Nephrocare IPO will be used for the following purposes:

1. Capital Expenditure: ₹129.11 Crore for setting up new dialysis clinics across India.
   
2. Debt Repayment: ₹136 Crore for the pre-payment or scheduled repayment of borrowings.
   
3. General Corporate Purposes: To pay for other business costs that come up because the company is growing and needs to run.

Nephrocare IPO Subscription and Lot Size

The Nephrocare IPO lot size for retail investors is 32 shares, and the minimum investment for the upper price band (₹460/share) is ₹14,016. Investors can apply for more than one lot, but the most they can get is 13 lots, which is ₹1,91,360.

From December 10 to December 12, 2025, people can sign up for the IPO. Regular updates will be made to the Nephrocare IPO subscription status, so investors can see how much demand there is and how many people have already signed up.

Nephrocare IPO Pricing and GMP

The Nephrocare IPO pricing range is between ₹438 and ₹460 per share, with a face value of ₹2. The Nephrocare IPO GMP (Grey Market Premium) will be changed based on how the market is doing as the IPO date gets closer. In the past, healthcare-related IPOs have been very popular, so investors need to keep up with the news to make good choices. 

Nephrocare Financials: A Snapshot

Nephrocare Health Services has done well financially in the past few years, which is likely to make investors more confident:

• Revenue: The company’s sales grew by 34%, from ₹574.72 Crore in FY 2024 to ₹769.92 Crore in FY 2025.
  
• Profit After Tax (PAT): Nephrocare’s PAT rose from ₹35.13 Crore in FY 2024 to ₹67.10 Crore in FY 2025, which is a huge increase.
  
• EBITDA Margin: The EBITDA margin went up to almost 22%, which shows that the company is doing well in terms of operations.

• Net Worth: Nephrocare’s net worth went up from ₹594.21 Crore in FY 2024 to ₹716.06 Crore in FY 2025.

Strengths of Nephrocare Health Services Ltd.

• Industry Leader: Nephrocare is the second-largest dialysis provider in India by treatments, partnering with major hospitals and operating across multiple centers.
  
• Recurring Revenue Model: As dialysis is a chronic requirement, Nephrocare enjoys high retention rates and predictable revenue from its patient base.
  
• Strong Growth: From a loss in FY23, the company turned profitable in FY25, reporting a 91% increase in PAT.
  
• Expansion Potential: With the rise in chronic kidney disease (CKD) cases in India, Nephrocare has substantial room for expansion into underserved regions.
  

Risks Involved in the Nephrocare IPO

While the Nephrocare IPO presents an attractive investment opportunity, there are certain risk factors to consider:

• Valuation Concerns: The IPO is priced at a P/E ratio of 63-162x, which is higher than the industry average. Investors need to consider whether the premium is justified by future growth potential.
• Debt Levels: The company has borrowings in the range of ₹207-225 Crore. While the IPO proceeds will help reduce debt, the leverage remains a key risk.
• Regulatory Risks: Government schemes and pricing caps, along with delays in reimbursement, can affect profitability.
• Competition: The dialysis sector in India is competitive, with major players like Apollo Hospitals and Fresenius Medical Care.

How to Apply for the Nephrocare IPO?

You can apply for the Nephrocare Health IPO through any of the following platforms:

• Investors can apply using ASBA (Application Supported by Blocked Amount) via net banking
  
• Alternatively, applications can be submitted through UPI using a registered broker/trading platform
  
• The IPO is open for Retail, HNI, and Institutional investor categories
  
• Select the number of lots (minimum 32 shares per lot)
  
• Enter the bid price within the prescribed price band
  
• Submit the IPO application before the closing date – 12th December 2025
  
• Upon submission, the application amount will be blocked until allotment is finalised
  
• Funds are debited only if shares are allotted after the basis of allotment is released

Ending Note 

The Nephrocare Health Services Ltd. IPO is a one-of-a-kind chance to invest in a top dialysis provider in India, a market that is predicted to develop a lot because more and more people are getting chronic kidney disease. Nephrocare is in a good position to keep growing because it has a robust financial history and a large network of clinics.

However, like with every IPO, it’s important to think about the dangers, especially when it comes to debt levels, market rivalry, and pricing. Before you make an investment, be sure to do your homework or talk to a financial professional.

Disclaimer

This article is intended for informational purposes only and does not constitute investment advice or a recommendation to apply for the IPO. Please read the Red Herring Prospectus (RHP) and consult a SEBI-registered financial advisor before making any investment decisions. For detailed disclosures and risk factors, refer to the official filings available on the SEBI website.

https://www.jainam.in/wp-content/uploads/2024/11/Disclosure-and-Disclaimer_Research-Analyst.pdf